Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07391657 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A Phase 3 study of Relapsed/Refractory Multiple Myeloma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
- 20
- Study locations
NCT07391657: Recruiting Phase 3 study of Relapsed/Refractory Multiple Myeloma, sponsored by AstraZeneca.
NCT07391657 is a Phase 3 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 508 participants, above the 136-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (274% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07391657, a Phase 3 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Primary Outcome
PFS: defined as time from randomisation until progression according to IMWG 2016 criteria as assessed by BICR, or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Carfilzomib
- BIOLOGICAL AZD0120
- DRUG Bortezomib
Study Locations (20)
Arizona
- Research Site - Gilbert
- Research Site - Phoenix
- Research Site - Tucson
Massachusetts
- Research Site - Boston
- Research Site - Boston
- Research Site - Boston
California
- Research Site - La Jolla
- Research Site - Santa Monica
Illinois
- Research Site - Chicago
- Research Site - Park Ridge
Colorado
- Research Site - Denver
Connecticut
- Research Site - New Haven
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2030-07-29 |
| Phase | Phase 3 |
What NCT07391657 shows while recruiting
NCT07391657 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, above the 136-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (274% higher).
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT07391657 names 20 study sites across 14 states, led by Arizona, Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT07391657 about?
NCT07391657 is a clinical study titled "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)". This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexam...
What is the current status of trial NCT07391657?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2026-02-23. Estimated completion is 2030-07-29.
What conditions does trial NCT07391657 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT07391657?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), AZD0120 (BIOLOGICAL), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT07391657?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07391657 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07391657's enrollment target sits among peer trials
508 1st of 14 higher than 14 of 14 other Relapsed/Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
COMPLETED · Phase 3
-
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
COMPLETED · Phase 3
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI